Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 69 of 6351
-
New hope for ovarian cancer: experimental drug AZD5335 faces off against standard care
Disease control Recruiting nowThe intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, expressing high or low FRα l…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New hope for stomach cancer: experimental drug JS107 enters final trial phase
Disease control Recruiting nowThis is a multicenter, randomized, controlled, open-label, Phase III study, designed to evaluate the efficacy and safety of JS107 versus investigator-selected therapy in the second-line or later treatment of patients with advanced gastric or gastroesophageal junction adenocarcino…
Phase 3 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New pill plus chemo aims to stop lung cancer comeback in patients with rare mutations
Disease control OngoingThe purpose of this study is to compare the efficacy of zipalertinib versus placebo in participants with early stage resected non-small cell lung cancer (NSCLC) harboring uncommon epidermal growth factor receptor mutation (EGFRmt).
Phase 3 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Simple blood test could spot 8 cancers early using AI
Diagnosis Recruiting nowThe purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients. This two-phase, multi-center observational study aims to identify specific transcriptomic biomarkers in p…
Sponsor: Javier Toledo • Aim: Diagnosis
Last updated Jun 27, 2026 08:08 UTC
-
New weekly shot could help shed pounds in major obesity trial
Disease control OngoingThis study investigates the efficacy and safety of once weekly injectable MET097 in adult participants with obesity or overweight with weight-related comorbidities excluding T2D. This trial will last for a duration of 84 weeks. The primary endpoint will be assessed after 64 weeks…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New hope for Hard-to-Treat prostate cancer: Immune-Targeting drug combo enters final testing
Disease control Recruiting nowThe purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans or death due to any cause) when compared to tre…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
BREAKTHROUGH: breast cancer patients may skip chemo thanks to new drug combo
Disease control Recruiting nowThe advent of CDK4/6 inhibitors (drugs designed to block the action of CDK4/6 proteins, which play a key role in cell proliferation) has improved treatment prospects for patients with metastatic breast cancer whose tumour cells express hormone receptors but not the HER2 protein (…
Phase 3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New weekly shot could help shed pounds without diabetes
Disease control Recruiting nowThe primary objective of the study is to determine the effects of ribupatide (KAI-9531) subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.
Phase 3 • Sponsor: Kailera • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New hope for rare lung cancer: targeted drug trial launches
Disease control Recruiting nowGlobal, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of firmonertinib at a dose level of 240 mg QD compared to investigator's choice of osimertinib (80 mg QD) or afatinib (40 mg QD) in participants who have locally advanced or metastatic N…
Phase 3 • Sponsor: ArriVent BioPharma, Inc. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Immune cell army takes on advanced melanoma in new trial
Disease control Recruiting nowA total of 92 subjects with advanced melanoma who met the inclusion criteria will be randomly assigned in a 1:1 ratio to the experimental group and the control group in this phase II trial. The study will be followed up until 24 months after treatment.
Phase 2 • Sponsor: Suzhou BlueHorse Therapeutics Co., Ltd. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a double immunotherapy beat standard care for a tough stomach cancer?
Disease control Recruiting nowA randomized controlled phase II study exploring first-line treatment options for recurrent/metastatic MSI-H gastric cancer
Phase 2 • Sponsor: Peking University • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Experimental gene therapy aims to help boys with rare muscle disease breathe easier
Disease control Recruiting nowX-linked myotubular myopathy (XLMTM) is a rare and serious condition present at birth where the muscles do not work properly. There are currently no approved therapies for XLMTM. The protein myotubularin is needed for muscle development, movement and breathing. A gene called MTM…
Phase 1/2 • Sponsor: Astellas Gene Therapies • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Promising malaria vaccine candidates enter key trial in african children
Vaccine OngoingThis is a Phase IIb randomised controlled trial of the safety, immunogenicity and efficacy of the malaria vaccine candidates R78C with Matrix-M™, and the combination of RH5.1 and R21 with Matrix-M™, in children aged 5-36 months in Burkina Faso.
Phase 2 • Sponsor: University of Oxford • Aim: Vaccine
Last updated Jun 27, 2026 11:01 UTC
-
Could this new vaccine stop shingles for years?
Vaccine OngoingThe purpose of the sutdy is to evaluate the protective efficacy of Recombinant Herpes Zoster Vaccine (CHO Cell) (hereinafter referred to as "the investigational vaccine") in preventing herpes zoster at 13-36 months after complete immunization with the 0- and 2-month immunization …
Phase 3 • Sponsor: MAXVAX Biotechnology Limited Liability Company • Aim: Vaccine
Last updated Jun 27, 2026 11:00 UTC
-
New pill aims to keep pancreatic cancer away after surgery
Disease control Recruiting nowThe purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.
Phase 3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Gene therapy Follow-Up: 15-Year watch for sickle cell patients
Disease control Recruiting nowThis is a Long-term Follow-up (LTFU) study in patients who received BEAM-101 in the parent study (Study BTX-AUT-001). Eligible patients who received BEAM-101 will be asked to participate in this LTFU study prior to completing Study BTX-AUT-001. Patients who enter into this study …
Sponsor: Beam Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Engineered immune cells take on tough lupus cases
Disease control Recruiting nowThis study is a single-arm, open-label clinical study designed to evaluate the safety and tolerability of QT-019B in subjects with refractory SLE and to determine the RD. The study has two phases: dose escalation and dose expansion, with a planned enrollment of 18-24 subjects.
Phase 1 • Sponsor: Hangzhou Qihan Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Proton beam vs. standard radiation: which is safer for advanced throat cancer?
Disease control Recruiting nowThis multicenter, open-label, randomized Phase III trial evaluates intensity-modulated proton therapy (IMPT) versus intensity-modulated photon radiotherapy (IMRT) in patients with newly diagnosed, high-risk, locoregionally advanced nasopharyngeal carcinoma. All patients receive …
Phase 3 • Sponsor: Man Hu • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New hope for bladder cancer: targeted drug combo trial launches
Disease control Recruiting nowThe purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will be administered in combination with enfortumab vedotin and p…
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New hope for lung cancer: experimental drug ZG006 takes on chemo
Disease control Recruiting nowThe main objective is to compare ZG006 with Investigator-Selected Chemotherapy on prolonging overall survival (OS).
Phase 3 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC